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Why do we need a statin trial in hemodialysis patients? (USRDS) [2] registry that of a total annual mortality of
Background. The risk of cardiovascular complications is 20%, 9% was due to mortality in CVD. The annual
markedly increased in patients on dialysis treatment. This in- mortality in CVD was reported to be 9%, with a preva-
cludes cardiac disease, stroke, and peripheral vascular disease.
lence of coronary artery disease in the HD populationThe mortality in dialysis patients is markedly higher compared
being 40%. In another small study based upon 432 dial-to a nonuremic population. There are several cardiovascular
(CV) risk factors that are unique to this population, one of ysis patients, a 22% prevalence of ischemic heart disease
which is dyslipidemia. Uremic patients do not usually develop (IHD) was found at the time of starting dialysis treat-
hypercholesterolemia, but rather are characterized by high lev- ment, along with an annual de novo IHD of 9%. The
els of very low density lipoprotein (VLDL) triglyerides, low
median survival time of dialysis patients was 44 monthshigh density lipoprotein (HDL) cholesterol, and elevated levels
if IHD was present, and 56 months in subjects withoutof modified low density lipoprotein (LDL) particles, which are
IHD history. [3]. In another study on 225 HD patientsparticularly harmful to the vascular wall. HMG-CoA reductase
inhibitors (statins) have been proven to be very efficient in followed for 31⁄2 years, a total mortality rate of 14% was
reducing CV events in a nonrenal population. There are several reported, as well as a 9% CVD mortality rate. The CVD
landmark trials that have demonstrated that statins reduce the event rate was 190/1000 patient years in this central Eu-mortality in cardiovascular disease (CVD) in populations with
ropean dialysis center [4]. Available evidence suggestsnormal, or close to normal, renal function. There are some
that an excess risk of CVD is present very early in theobservational registry data indicating that this may also be true
in hemodialysis (HD) patients, but no prospective controlled natural history of chronic renal failure [5] and about one
trial has been performed to date. third of patients with mild renal impairment (glomerular
Methods. We present the rationale for, and a brief outline filtration rate [GFR] 50 mL/min) were found to haveof, a randomized placebo-controlled trial using a novel drug,
a history of overt CVD [6]. It has been well recognizedrosuvastatin, in HD patients, to target cardiovascular events
that the morbidity and mortality in CVD differs between(the AURORA study). This study will include close to 3000
male and female HD patients, aged 50-80 years. The study is various countries. Thus, the frequency is substantially
event driven and it has been estimated that it will run for a lower in southern Europe (differs by a factor 3), com-
follow-up time close to four years. pared with northern Europe, in patients on renal replace-
Conclusion. There is a sound rationale for making a random-
ment therapy. The corresponding figures for Northized placebo-controlled statin trial in HD patients, with the
America coincide with northern Europe.objective to demonstrate an effect on CV mortality and mor-
bidity.
CARDIOVASCULAR RISK FACTORS
BACKGROUND IN UREMIA
Patients with chronic kidney disease are at a high risk The risk factor pattern for development of CVD in-
for developing premature cardiovascular disease. Car- cludes traditional and nontraditional risk factors. In renal
diac mortality among dialysis patients younger than 45 patients, risk factors such as age, hypertension, diabetes,
years is about 100 times greater than in the general US and dyslipidemia [7] have been reported to be prominent
population [1]. This large proportional increase in risk risk factors for the development of CVD (Fig. 1). Total
implies that the absolute risk of cardiac death in young cholesterol level does not correlate with the risk of CVD
dialysis patients is comparable to that observed in elderly in this patient population, however. Renal patients have
individuals without renal disease. It has also been re- a different lipoprotein pattern, with increased levels of
ported from the United States Renal Data System the VLDL triglycerides, Lp(a) and apoB, and character-
istically low levels of HDL cholesterol and apoA1. This
pattern is compatible with high concentrations of reac-Key words: hemodialysis, cardiovascular disease, dyslipidemia, rosu-
vastatin. tive and aggressive small dense LDL particles. Patients
with renal insufficiency also suffer from increased oxida- 2003 by the International Society of Nephrology
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Fig. 1. Proposed interaction of risk factors and
mechanisms of accelerated atherosclerosis in
uremia. There is a contribution by the increased
formation of mediators of oxidative stress, accu-
mulation of ADMA, malnutrition, and inflam-
mation in uremia, leading to the rapid develop-
ment of atherosclerosis and vascular disease.
Lipoprotein abnormalities are particularly dom-
inated by the formation of atherogenic lipid
fractions due to oxidative modification of lipo-
proteins and formation of small dense LDL par-
ticles. An influence by immunodeficiency can
be anticipated based on the role of the immune
response in atherogenesis, but has not yet been
well characterized in uremia. Abbreviations are:
TG, triglycerides; HDL, high density lipoprotein;
LDL, low density lipoprotein; ROS, reactive oxy-
gen species; AGEs, advanced glycation end prod-
ucts, AOPP, advanced oxidation of plasma pro-
teins; ADMA, asymmetric dimethylarginine.
tive stress, possibly induced by uremic toxins. This leads RATIONALE
to high levels of oxidized glutathione and advanced gly- Statin treatment has been proven to reduce the mortal-
cation end products (AGEs) and, conversely, low levels ity and morbidity in cardiovascular disease, both in pri-
of antioxidative capacity that include a shortened lag mary and secondary prevention settings [15–17]. How-
time of diene conjugation and a more rapid oxidation ever, in none of these full-scale statin trials were patients
of lipoprotein fractions [8–10]. A state of oxidative stress with a significant renal impairment included. This is espe-
has been associated with malnutrition in renal patients, cially true regarding patients subjected to renal replace-
and could contribute to the state of increased inflamma- ment therapy. The ALERT study [18] in renal transplant
tory activity reported in renal insufficiency and associ- patients using fluvastatin, and the 4D study [19] in type
ated with the development of atherosclerotic vascular 2 diabetic patients on HD treatment using atorvastatin,
disease [11]. Malnutrition could very well be combined are ongoing. The CHORUS study was initiated using
with a relative vitamin deficiency, leading to reduced cerivastatin in HD patients, but stopped in 2001 when
antioxidative capacity, which could be the association cerivastatin was withdrawn from the market. In addition,
between malnutrition and enhanced inflammation, re- it has recently been reported that total and CV mortality
flected by increased levels of C-reactive protein (CRP), were 32% and 36% lower among ESRD patients receiv-
tumor necrosis factor  (TFNa), and inter cellular adhe- ing a statin, when compared to not receiving a statin,
respectively, based upon observational registry data [20].sion molecule-1 (ICAM-1) [12]. Another factor that has
been reported to be related to development of CVD, The magnitude of these apparent benefits were in the
range observed in the 4S study, and other studies ofincluding atherosclerotic disease, IHD, and CHF, is en-
dothelial dysfunction, which is tightly associated with the hypercholesterolemic patients with CHD but normal or
near normal renal function [15, 17].degree of renal insufficiency [13]. Furthermore, it was
recently shown that the degree of oxidative stress is re- Recognizing that there is no data obtained from pro-
spective studies of statin treatment in patients receivinglated to reduced endothelial function in preuremic pa-
tients, and the antioxidative capacity positively related HD treatment, there is evidence that these agents favor-
ably alter the atherogenic lipid profile and can be usedto endothelial-dependent vasodilation [14]. This could
possibly be the link between the state of inflammation, in this population. Statins have proved to be safe, well
tolerated, and effective in reducing both total and CHDendothelial dysfunction, and future development of
CVD. A primary defect in the nitric oxide synthesis could mortality in high-risk patients with normal or near nor-
mal renal function, in patients both with, and without,be caused by high levels of asymmetric dimethylarginine
(ADMA), which are increased in renal insufficiency due preexisting CHD. The safety or CV risk-reducing effi-
cacy of lipid-altering drug treatment has not been provedto an accumulation of ADMA, and reduced catabolism
of ADMA due to a deficiency in dimethylarginine di- in randomized prospective studies of patients receiving
HD, however. Furthermore, total cholesterol and LDL-methylaminohydrolase (DDAH), basically formed in re-
nal tissue [4]. cholesterol levels do not appear to predict CVD risk in
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